Influence of Patient, Physician, and Hospital Characteristics on the Receipt of Guideline-Concordant Care for Inflammatory Breast Cancer
Published Date:Nov 21 2015
Source:Cancer Epidemiol. 40:7-14.
Pubmed Central ID:PMC4738104
Funding:P30 CA014520/CA/NCI NIH HHS/United States
P30CA014520/CA/NCI NIH HHS/United States
T32 GM008692/GM/NIGMS NIH HHS/United States
T32GM008692/GM/NIGMS NIH HHS/United States
TL1 TR000429/TR/NCATS NIH HHS/United States
U01 DP000261/DP/NCCDPHP CDC HHS/United States
U01DP000261/DP/NCCDPHP CDC HHS/United States
UL1 TR000427/TR/NCATS NIH HHS/United States
Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care.
Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics.
Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (≥70 years), non-white race, normal body mass index (BMI 18.5–25 kg/m2), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p=0.06) or 2013 (p=0.06) NCCN guidelines.
Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and postoperative radiation therapy is also crucial.
Supporting Files:No Additional Files
You May Also Like: